Our results suggest that aloperine could be developed as a lead compound or adjuvant chemotherapy drug to treat ICC harboring the mutant IDH, which is crucial for its further development and utilization. This evidence concerns the gene IDH1 and intrahepatic cholangiocarcinoma.